Oxycodone and Acetaminophen Tablets side effects: what 11,842 FDA adverse event reports show
Drug class
Not stated in label
Label matched
Oxycodone (Oxycodone Hydrochloride)
Who reports
11,842 reports · 70% serious · 1,570 with death outcome · 63% female
Used for
Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.
What it is
Oxycodone HCl tablets, USP contains oxycodone, an opioid agonist.
Boxed warning
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,054 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Vision abnormal neonatal | 71 | 357.1 276.8–460.7ROR 359.2 · calibrated p 4e-12 ✓ | 274.7 EB05 225.1 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious n=71 · 100% consumer | no trial arm names this drug |
| Grip strength | 38 | 347.2 245.2–491.6ROR 348.3 · calibrated p 9e-12 ✓ | 253.0 EB05 192.4 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=38 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Swollen joint count | 29 | 236.5 160.5–348.4ROR 237.1 · calibrated p 4e-10 ✓ | 183.4 EB05 133.9 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=29 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Neonatal hypoacusis | 26 | 220.3 146.5–331.1ROR 220.8 · calibrated p 8e-10 ✓ | 171.3 EB05 122.8 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=26 · ♀ 38% (drug 63%) · 100% consumer | no trial arm names this drug |
| Sleep disorder due to general medical condition, hypersomnia type | 10 | 196.1 102.0–376.9ROR 196.3 · calibrated p 1e-8 ✓ | 132.5 EB05 76.9 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=10 | no trial arm names this drug |
| Deep vein thrombosis postoperative | 184 | 183.3 157.6–213.1ROR 186.2 · calibrated p 9e-10 ✓ | 163.2 EB05 144.3 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious n=184 · ♀ 100% (drug 63%) · 96% clinician | no trial arm names this drug |
| Lupus vulgaris | 100 | 162.3 132.4–199.1ROR 163.7 · calibrated p 3e-9 ✓ | 144.6 EB05 122.3 · IC025 +6.1 3/3 methods agree | Not in label — unassessed | serious n=100 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 521 | 155.9 142.8–170.2ROR 163.0 · calibrated p 2e-9 ✓ | 142.4 EB05 132.4 · IC025 +6.8 3/3 methods agree | Labeled (related wording) related wording | serious n=520 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Subcutaneous drug absorption impaired | 44 | 155.4 114.3–211.5ROR 156.0 · calibrated p 7e-9 ✓ | 134.6 EB05 104.4 · IC025 +5.3 3/3 methods agree | Labeled (related wording) related wording | serious n=44 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Muscle injury | 621 | 144.9 133.8–156.9ROR 152.8 · calibrated p 4e-9 ✓ | 133.3 EB05 124.7 · IC025 +6.8 3/3 methods agree | Labeled (related wording) related wording | serious PRR 119.7 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 539 | 140.3 128.7–152.8ROR 146.9 · calibrated p 6e-9 ✓ | 129.3 EB05 120.4 · IC025 +6.7 3/3 methods agree | Not in label — unassessed | serious PRR 107.2 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 49 | 140.2 104.8–187.4ROR 140.8 · calibrated p 2e-8 ✓ | 123.7 EB05 97.3 · IC025 +5.3 3/3 methods agree | Lab value / disease marker | serious n=49 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| X-ray abnormal | 130 | 139.0 116.4–166.1ROR 140.5 · calibrated p 1e-8 ✓ | 126.5 EB05 109.3 · IC025 +6.1 3/3 methods agree | Lab value / disease marker | serious n=130 · ♀ 100% (drug 63%) · 95% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 517 | 138.9 127.2–151.6ROR 145.1 · calibrated p 6e-9 ✓ | 128.1 EB05 119.1 · IC025 +6.7 3/3 methods agree | Lab value / disease marker | serious PRR 106.7 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Adjustment disorder with depressed mood | 145 | 137.2 115.9–162.3ROR 138.8 · calibrated p 1e-8 ✓ | 125.2 EB05 109.0 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious n=145 · ♀ 100% (drug 63%) · 96% clinician | no trial arm names this drug |
| C-reactive protein | 63 | 132.0 102.2–170.4ROR 132.7 · calibrated p 2e-8 ✓ | 118.5 EB05 95.9 · IC025 +5.6 3/3 methods agree | Lab value / disease marker | serious n=63 · ♀ 100% (drug 63%) · 95% clinician | no trial arm names this drug |
| Swollen joint count increased | 200 | 121.2 105.2–139.8ROR 123.3 · calibrated p 3e-8 ✓ | 112.2 EB05 99.8 · IC025 +6.2 3/3 methods agree | Lab value / disease marker | serious n=200 · ♀ 100% (drug 63%) · 96% clinician | no trial arm names this drug |
| Learning disability | 339 | 118.7 106.5–132.3ROR 122.1 · calibrated p 3e-8 ✓ | 110.5 EB05 101.0 · IC025 +6.4 3/3 methods agree | Not in label — unassessed | serious n=339 · ♀ 40% (drug 63%) · 100% consumer | no trial arm names this drug |
| Dislocation of vertebra | 137 | 116.1 97.8–137.9ROR 117.5 · calibrated p 4e-8 ✓ | 107.3 EB05 93.1 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious n=137 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Folliculitis | 634 | 115.7 107.0–125.2ROR 122.2 · calibrated p 2e-8 ✓ | 108.2 EB05 101.4 · IC025 +6.5 3/3 methods agree | Not in label — unassessed | serious PRR 105.5 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Porphyria acute | 77 | 104.5 83.1–131.4ROR 105.2 · calibrated p 1e-7 ✓ | 96.4 EB05 79.6 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=77 · ♀ 100% (drug 63%) · 92% clinician | no trial arm names this drug |
| Helicobacter infection | 553 | 101.5 93.3–110.4ROR 106.4 · calibrated p 7e-8 ✓ | 95.7 EB05 89.2 · IC025 +6.3 3/3 methods agree | Not in label — unassessed | serious PRR 83.7 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Facet joint syndrome | 162 | 95.8 81.9–112.1ROR 97.2 · calibrated p 2e-7 ✓ | 90.0 EB05 78.9 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious n=162 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Rheumatic fever | 217 | 92.5 80.8–105.9ROR 94.2 · calibrated p 2e-7 ✓ | 87.2 EB05 77.9 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious n=217 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Retinitis | 76 | 84.4 67.1–106.1ROR 84.9 · calibrated p 5e-7 ✓ | 79.0 EB05 65.2 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=76 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Pemphigus | 559 | 83.3 76.7–90.5ROR 87.4 · calibrated p 3e-7 ✓ | 79.3 EB05 74.0 · IC025 +6.1 3/3 methods agree | Not in label — unassessed | serious PRR 66.0 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Hand deformity | 561 | 79.3 73.0–86.1ROR 83.2 · calibrated p 5e-7 ✓ | 75.7 EB05 70.6 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious PRR 68.2 · ♀ 99% (drug 63%) · 93% clinician | no trial arm names this drug |
| Rheumatoid factor positive | 221 | 70.5 61.7–80.5ROR 71.8 · calibrated p 1e-6 ✓ | 67.4 EB05 60.3 · IC025 +5.7 3/3 methods agree | Lab value / disease marker | serious n=221 · ♀ 100% (drug 63%) · 95% clinician | no trial arm names this drug |
| Developmental delay | 346 | 69.9 62.9–77.8ROR 72.0 · calibrated p 1e-6 ✓ | 67.0 EB05 61.3 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious PRR 56.4 · ♀ 42% (drug 63%) · 100% consumer | no trial arm names this drug |
| Peripheral venous disease | 151 | 69.5 59.1–81.7ROR 70.4 · calibrated p 2e-6 ✓ | 66.4 EB05 57.9 · IC025 +5.5 3/3 methods agree | Labeled (related wording) related wording | serious n=151 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Presbyacusis | 11 | 64.9 35.5–118.4ROR 64.9 · calibrated p 1e-5 ✓ | 56.7 EB05 33.8 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=11 | no trial arm names this drug |
| Pericarditis | 552 | 60.6 55.8–65.8ROR 63.5 · calibrated p 3e-6 ✓ | 58.5 EB05 54.5 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious PRR 48.8 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Irritable bowel syndrome | 635 | 54.2 50.2–58.5ROR 57.2 · calibrated p 6e-6 ✓ | 52.5 EB05 49.2 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious PRR 54.9 · ♀ 99% (drug 63%) · 92% clinician | no trial arm names this drug |
| Synovitis | 533 | 53.8 49.5–58.6ROR 56.3 · calibrated p 6e-6 ✓ | 52.2 EB05 48.5 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious PRR 45.2 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Substance use disorder | 83 | 49.1 39.5–61.0ROR 49.4 · calibrated p 2e-5 ✓ | 47.3 EB05 39.3 · IC025 +4.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=82 · 100% consumer | no trial arm names this drug |
| Glossodynia (burning tongue/mouth pain) | 562 | 45.6 42.0–49.5ROR 47.8 · calibrated p 2e-5 ✓ | 44.4 EB05 41.4 · IC025 +5.3 3/3 methods agree | Labeled (related wording) related wording | serious PRR 52.9 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| C-reactive protein abnormal | 161 | 45.6 39.0–53.3ROR 46.2 · calibrated p 2e-5 ✓ | 44.2 EB05 38.8 · IC025 +5.0 3/3 methods agree | Lab value / disease marker | serious n=161 · ♀ 100% (drug 63%) · 92% clinician | no trial arm names this drug |
| Bone erosion | 88 | 45.1 36.5–55.6ROR 45.4 · calibrated p 3e-5 ✓ | 43.6 EB05 36.4 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=88 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Drug withdrawal syndrome neonatal | 369 | 44.7 40.4–49.5ROR 46.1 · calibrated p 2e-5 ✓ | 43.6 EB05 40.0 · IC025 +5.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 36.2 · ♀ 43% (drug 63%) · 100% consumer | no trial arm names this drug |
| Autoimmune disorder | 193 | 36.4 31.6–41.9ROR 37.0 · calibrated p 9e-5 ✓ | 35.6 EB05 31.5 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious PRR 31.6 · ♀ 98% (drug 63%) · 94% clinician | no trial arm names this drug |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Pain | 1,481 | 4.3 4.1–4.5ROR 4.7 · calibrated p 0.266 | 4.3 EB05 4.1 · IC025 +2.0 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 4.7 | no trial arm names this drug |
| Fatigue (tiredness) | 1,437 | 3.3 3.1–3.4ROR 3.6 · calibrated p 0.463 | 3.3 EB05 3.1 · IC025 +1.6 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 4.0 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 1,417 | 1.9 1.8–2.0ROR 2.0 · calibrated p 0.960 | 1.9 EB05 1.8 · IC025 +0.8 | Reporting / coding artifact | serious PRR 2.6 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 1,058 | 3.3 3.1–3.5ROR 3.5 · calibrated p 0.475 | 3.3 EB05 3.1 · IC025 +1.6 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.4 · ♀ 84% (drug 63%) | no trial arm names this drug |
| Nausea | 985 | 2.2 2.1–2.3ROR 2.3 · calibrated p 0.893 | 2.2 EB05 2.1 · IC025 +1.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.3 | no trial arm names this drug |
| Arthralgia (joint pain) | 968 | 4.1 3.9–4.4ROR 4.4 · calibrated p 0.308 | 4.1 EB05 3.9 · IC025 +1.9 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 5.4 · ♀ 88% (drug 63%) | no trial arm names this drug |
| Headache | 902 | 2.6 2.4–2.7ROR 2.7 · calibrated p 0.740 | 2.5 EB05 2.4 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.2 · ♀ 85% (drug 63%) | no trial arm names this drug |
| Rash | 872 | 3.6 3.3–3.8ROR 3.8 · calibrated p 0.424 | 3.6 EB05 3.4 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 5.9 · ♀ 90% (drug 63%) | no trial arm names this drug |
| Pruritus (itching) | 856 | 4.0 3.8–4.3ROR 4.2 · calibrated p 0.335 | 4.0 EB05 3.8 · IC025 +1.9 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 7.1 · ♀ 93% (drug 63%) | no trial arm names this drug |
| Peripheral swelling | 823 | 9.5 8.9–10.2ROR 10.2 · calibrated p 0.031 ✓ | 9.5 EB05 8.9 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 12.7 · ♀ 92% (drug 63%) | no trial arm names this drug |
| Pyrexia (fever) | 821 | 4.2 3.9–4.5ROR 4.4 · calibrated p 0.305 | 4.2 EB05 4.0 · IC025 +2.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 4.2 · ♀ 91% (drug 63%) | no trial arm names this drug |
| Diarrhoea (diarrhea) | 806 | 2.2 2.1–2.4ROR 2.3 · calibrated p 0.899 | 2.2 EB05 2.1 · IC025 +1.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.4 | no trial arm names this drug |
| Nasopharyngitis (common cold) | 793 | 7.6 7.1–8.2ROR 8.1 · calibrated p 0.064 | 7.6 EB05 7.1 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious PRR 13.0 · ♀ 95% (drug 63%) | no trial arm names this drug |
| Infection | 790 | 9.7 9.1–10.4ROR 10.4 · calibrated p 0.029 ✓ | 9.7 EB05 9.1 · IC025 +3.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 9.8 · ♀ 95% (drug 63%) | no trial arm names this drug |
| Joint swelling | 770 | 11.4 10.6–12.2ROR 12.1 · calibrated p 0.016 ✓ | 11.3 EB05 10.6 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 15.6 · ♀ 96% (drug 63%) | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Vision abnormal neonatal — n=71, PRR 357.1
- Grip strength — n=38, PRR 347.2
- Swollen joint count — n=29, PRR 236.5
- Neonatal hypoacusis — n=26, PRR 220.3
- Deep vein thrombosis postoperative — n=184, PRR 183.3
- Lupus vulgaris — n=100, PRR 162.3
- Duodenal ulcer perforation — n=539, PRR 140.3
- Adjustment disorder with depressed mood — n=145, PRR 137.2
- Learning disability — n=339, PRR 118.7
- Dislocation of vertebra — n=137, PRR 116.1
✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Oxycodone and Acetaminophen Tablets?
In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone and Acetaminophen Tablets are pain, fatigue, dyspnoea, nausea, arthralgia, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Oxycodone and Acetaminophen Tablets have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Do FAERS signals prove that Oxycodone and Acetaminophen Tablets causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 6b6db42b-9821-4aa6-8566-297037d84079, effective 20260723; matched on
openfda.generic_name.exact:"OXYCODONE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,094 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
OXYCODONE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.